Gambaran Penggunaan Obat Pada Pasien Diabetes Mellitus Tipe 2 DI Intalasi Rawat Jalan RS dr. Oen Solo Baru Periode Januari-Juni 2023
Keywords:
Diabetes Mellitus, Overview, Drugs, Groups, HospitalAbstract
Diabetes mellitus (DM) is a widespread health problem and continues to increase every year. Management of DM involves implementing a healthy lifestyle, increasing physical activity, and pharmacological therapy. The aim of this research was to determine the description of drug use in patients with type 2 diabetes mellitus in the outpatient installation of Dr. Hospital. Oen Solo Baru for the period January-June 2023. This research is a non-experimental descriptive research design where data is collected retrospectively. Data analysis uses quantitative research which is presented in the form of a table of number of cases and percentage (%). The number of samples in this study was 100 medical record data. The results of the study showed that there were 5 types of antihyperglycemia drugs used, namely the Sulfonylurea group with (42%), Biguanid (28%), Insulin (12%), DPP-4 Inhibitors (10%), and α-glucosidase Inhibitors (8%) . The conclusion of this study is that the most frequently used antihyperglycemia drugs are sulfonylureas (42%) and the least frequently used are a-gluoxidase inhibitors (8%).
Downloads
References
S. A. Nasution F., Andilala, “Faktor Risiko Kejadian Diabetes Mellitus,” J. Ilmu Kesehat., vol. 9, no. 2, pp. 94–102, 2021.
F. Megawati, N. P. D. Agustini, and N. L. P. D. Krismayanti, “Studi Retrospektif Terapi Antidiabetik Pada Penderita Diabetes Melitus Rawat Inap Di Rumah Sakit Umum Ari Canti Periode 2018,” J. Ilm. Medicam., vol. 6, no. 1, pp. 28–32, 2020, doi: 10.36733/medicamento.v6i1.718.
J. T. Dinas Kesehatan Provinsi, “Profil Kesehatan Jawa Tengah 2011,” 2022.
Kemnkes RI, “Kemenkes RI No 7 Tentang Pedoman Nasional Pelayan Kedokteran Tata Laksana Diabetes Mellitus Tipe 2 Dewasa,” Pedoman Nas. Pelayan Kedokt. Tata Laksana Diabetes Mellit. Tipe 2 Dewasa, pp. 1–183, 2020.
B. S. Annisa, C. E. Puspitasari, and S. R. Aini, “Profil penggunaan obat antidiabetes pada pasien diabetes mellitus tipe 2 di instalasi rawat jalan RSUD Provinsi NTB tahun 2018,” Sasambo J. Pharm., vol. 2, no. 1, pp. 37–41, 2021, doi: 10.29303/sjp.v2i1.74.
Nurul Maulidya and D. Oktianti, “Pola Penggunaan Obat Antidiabetes di Puskesmas Grabag Magelang,” J. Holistics Heal. Sci., vol. 3, no. 1, pp. 51–59, 2021, doi: 10.35473/jhhs.v3i1.71.
S. K. Rachman, T. Bhatara, and E. Hendryanny, “Scoping Review : Hubungan Kontrol Glikemik ( HbA1C ), Durasi Penyakit , dan Profil Lipid pada Pasien Diabetes Melitus Tipe II dengan Kejadian Neuropati Diabetik Scoping Review : Relationship of Glycemic Control ( HbA1C ), Disease Duration , and Lipid Prof,” J. Integr. Jesehatan dan Sains, vol. 3, no. 22, pp. 207–214, 2021.
S. Soelistijo, “Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021,” Glob. Initiat. Asthma, p. 46, 2021, [Online]. Available: www.ginasthma.org.
T. Kurniawati, D. Lestari, A. P. Rahayu, F. N. Syaputri, T. Daru, and A. Tugon, “Evaluasi Profil Penggunaan Obat Antidiabetes Pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan di Salah Satu Rumah Sakit Kabupaten Bogor,” J. Sci. Technol. Entrep., vol. 3, no. 1, pp. 24–34, 2021, [Online]. Available: https://ejournal.umbandung.ac.id/index.php/jste/article/view/168
D. Malihah and R. Emelia, “Pola Pengobatan Antidiabetes Terhadap Pasien Diabetes Melitus Tipe II Rawat Jalan di RSAU dr. M. Salamun,” J. Delima Harapan, vol. 9, no. 1, pp. 83–95, 2022.
E. Setyorini, E. D. Irawan, L. Oktora, and R. Kumala, “Optimasi Hydroxypropyl Methylcellulose dan Xanthan Gum pada Tablet Floating-Mucoadhesive Gliclazide Metode Desain Faktorial ( Optimization of Hydroxypropyl Methylcellulose and Xanthan Gum on Floating-Mucoadhesive Gliclazide Tablet using Factorial Design ),” e-Jurnal Pustaka Kesehat., vol. 4, no. 2, pp. 249–254, 2016.
A. Putri Maria Natasya Panamuan, E. Kartika Untari, S. Rizkifan Program Studi Farmasi, F. Kedokteran, and U. Tanjungpura Jl Hadari Nawawi, “Pengaruh Usia Pasien dan Dosis terhadap Efek Samping Metformin pada Pasien Diabetes Tipe 2,” J. Farm. Komunitas, vol. 8, no. 2, pp. 51–58, 2021.
M. S. Panggabean, “Tinjauan atas Ezelin ® – Biosimilar Insulin Glargine Pertama di Indonesia,” Cermin dunia Kedokt., vol. 45, no. 10, pp. 784–788, 2018.
